1. Home /
  2. Drug Approvals

Drug Approvals

Back to Back Wins for Bristol-Myers, and Here's How I'd Trade It

BMY sees reason for optimism over the final half of the year.

Let's Not Overlook AbbVie's Q2 Beat

There is no thought of selling here and now, even with politicized pressure on the industry.

Here's My Biotechnology Shopping List

Biotechnology is always high risk but the right plays move unlike anything else.

Totally Out There: Our Top 5 Psychedelic Stocks

Investors are anxious to grab the next penny stock that may be poised to jump on the mind-blowing bubble. Here they are.

A Rally to $21 on Takeda Pharmaceutical Would Be Bullish

Let's review the charts and indicators.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Sorrento Therapeutics Has Made a Large Base Formation - Timing Is Key

The question is when to buy and what to risk.

AstraZeneca Could Continue to Higher Highs

Oxford University, along with Britain's AstraZeneca, published promising data from an early stage trial of a key coronavirus vaccine study Monday in London.

Taking a Wait and Watch Strategy on Biohaven Pharmaceutical

BHVN has made a relatively big advance since April and a period of consolidation or sideways price action is probably likely at this time.

These 3 Biotechs Have Decent Values

One would need to use covered calls to initiate positions that provide a solid amount of downside protection.